



Contact: Christine Stroup
Kovak-Likly Communications
(203) 762-8833 or
CStroup@KLCpr.com

FOR IMMEDIATE RELEASE

WIN A \$10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

Ferring Pharmaceuticals Announces 2006 My Little Miracle Essay Contest

If you are a mom who has successfully given birth using Ferring Pharmaceuticals' infertility products, you can win a \$10,000 education fund or one of 11 other prizes to support your child's future. To be eligible, all you need to do is write a brief essay on your journey to achieve parenthood and its impact on your life.

Ferring's My Little Miracle Essay Contest is open to women who have been successfully treated with BRAVELLE[®] (urofollitropin for injection, purified), MENOPUR[®] (menotropins for injection, USP), REPRONEX[®] (menotropins for injection, USP), or a combination of these medications. The contest celebrates the miracle of birth for these mothers who have faced infertility and continues Ferring's tradition of providing value to their patients by offering education funds for the winners' children.

Ferring is also awarding a \$2,500 education fund to the runner up and 10 honorable mention winners will each receive \$500. Since announcing the first contest in 2004, Ferring has awarded \$50,000 in education funds to its winners.

Essays should not exceed 800 words, must be written in English, include the entrant's name, address, phone number and age, as well as the child(ren)'s name and age(s) and be submitted with a contest application and labeled photo. Entries must be postmarked by June 30, 2006. Winners will be announced at the 62nd Annual Meeting of the American Society for Reproductive Medicine (ASRM), October 21-25, 2006.

For more details and a contest application visit www.ferringfertility.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

-more-

BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0%, 3.8% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE®, MENOPUR® and/or REPRONEX® may result in multiple gestations.

###